阿糖胞苷分别联合伊达比星与柔红霉素治疗急性非淋巴细胞白血病 成本效果分析比较

本研究目的是比较伊达比星联合阿糖胞苷（IA）与柔红霉素联合阿糖胞苷（DA）治疗成人急性非淋巴细胞白血病的效果、住院总费用并进行成本效果分析，从而解决综合成本和效果考虑两种方案中哪种是更加可取的这一问题。回顾性选取了102例成人急性非淋巴细胞白血病患者，分别给予一疗程伊达比星联合阿糖胞苷或者柔红霉素联合阿糖胞苷的3+7模式治疗，统计治疗效果和住院期间各项费用，结果IA组完全缓解率和有效率均高于DA组（60.00% vs. 30.56%，86.67% vs. 69.44%），但是因为伊达比星的费用远高于柔红霉素，IA组患者住院总费用显著高于DA组（P<0.05），成本效果分析显示IA方案优于DA方案，也就是说在与阿糖胞苷联用时伊达比星与柔红霉素相比是更加有效经济的药物，值得在临床上推广应用。

Cost effectiveness analysis of idarubicin and daunorubicin combined with cytarabine in the treatment of acute non-lymphocytic leukemia

The purpose of this study is to compare effect and cost of idarubicin combined with cytarabine (IA) or daunorubicin combined with cytarabine (DA) treatment in adult patients with acute non-lymphocytic leukemia, so as to know which is more desirable in the two schemes considering cost and effect. Review of 102 cases of adult acute non-lymphocytic leukemia patients, were given a course of idarubicin combined with cytarabine or daunorubicin combined with cytarabine in 3+7 mode treatment. Analyzed therapeutic efficacy and the cost of hospitalization period, that results is IA group complete remission rate and effective rate were higher than that in the DA group (60.00% vs. 30.56%, 86.67% vs. 69.44%), but because the price of idarubicin is much higher than that of daunorubicin, total cost of IA group was significantly higher than that of DA group (P<0.05). That is to say idarubicin is more effective and economic than daunorubicin when combined with cytarabine, and it is worth promoting the use in clinic.